Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06547619 · ClinicalTrials.gov registry record · Early Phase 1

Role of ET-1, Physical Activity, and Sedentary Behavior in Microvascular Dysfunction Following GDM

A Early Phase 1 study of Physical Inactivity and Endothelial Dysfunction, sponsored by Anna Stanhewicz, PhD.

Recruiting
Registry status
Early Phase 1
Development phase
40
Enrollment target
1
Study location

NCT06547619 is a Early Phase 1 study of Physical Inactivity and Endothelial Dysfunction that is actively recruiting participants, run by Anna Stanhewicz, PhD. The registered enrollment target is 40 participants, below the 224-participant average among 59 other Physical Inactivity trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06547619, a Early Phase 1 study of Physical Inactivity and Endothelial Dysfunction, is actively recruiting participants, sponsored by Anna Stanhewicz, PhD.

RECRUITING
Registry status
Early Phase 1
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

Women with a history of gestational diabetes mellitus (GDM) are at a 2-fold greater risk for the development of overt cardiovascular disease (CVD) following the effected pregnancy. While subsequent development of type II diabetes elevates this risk, prior GDM is an independent risk factor for CVD morbidity, particularly, within the first decade postpartum. GDM is associated with impaired endothelial function during pregnancy and decrements in macro- and microvascular function persist postpartum, despite the remission of insulin resistance following delivery. Collectively, while the association between GDM and elevated lifetime CVD risk is clear, and available evidence demonstrates a link between GDM and vascular dysfunction in the decade following pregnancy, the mechanisms mediating this persistent dysfunction remain unexamined. The purpose of this investigation is to examine the role of endothelin-1, a potent vasoconstrictor, in aberrant microvascular function in otherwise healthy women with a history of GDM and to identify whether this mechanism is influenced by physical activity and sedentary behavior.

Interventions

  • DRUG Insulin aspart

Study Locations (1)

Iowa

  • University of Iowa - Iowa City

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2024-10-01
Est. Completion 2027-05
Phase Early Phase 1

Sponsor

Anna Stanhewicz, PhD

14 total trials

What the Registry Record Tells You About NCT06547619

The ClinicalTrials.gov registry entry for NCT06547619 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 224-participant average among 59 other Physical Inactivity trials with a reported enrollment target (82% lower). The listed sponsor is Anna Stanhewicz, PhD, which has 14 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Physical Inactivity appearing as the primary indexed condition, and to 1 intervention - of which Insulin aspart is the first listed.

NCT06547619 reports 1 study location spanning 1 distinct geographic area - top geographies include Iowa.

Frequently Asked Questions

What is clinical trial NCT06547619 about?

NCT06547619 is a clinical study titled "Role of ET-1, Physical Activity, and Sedentary Behavior in Microvascular Dysfunction Following GDM". Women with a history of gestational diabetes mellitus (GDM) are at a 2-fold greater risk for the development of overt cardiovascular disease (CVD) following the effected pregnancy. While subsequent development of type II diabetes elevates this risk, prior GDM is an independent risk factor for CVD mo...

What is the current status of trial NCT06547619?

This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 40 participants. The study started on 2024-10-01. Estimated completion is 2027-05.

What conditions does trial NCT06547619 study?

This clinical trial studies the following conditions: Physical Inactivity, Endothelial Dysfunction, Gestational Diabetes.

What interventions are being tested in trial NCT06547619?

The interventions under investigation include: Insulin aspart (DRUG).

Who is sponsoring clinical trial NCT06547619?

This trial is sponsored by Anna Stanhewicz, PhD, which has 14 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06547619 being conducted?

This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Physical Inactivity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.